Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer

Full text
Author(s):
Show less -
Visacri, Marilia B. [1] ; Quintanilha, Julia C. F. [1] ; de Sousa, Vanessa M. [2] ; Amaral, Lais S. [1] ; Ambrosio, Rosiane de F. L. [1] ; Calonga, Luciane [3] ; Curi, Silvia F. B. B. [3] ; Leme, Mayra F. de T. [3] ; Chone, Carlos T. [3] ; Altemani, Joao M. C. [3] ; Mazzola, Priscila G. [2] ; Malaguti, Carina [1] ; Vercesi, Anibal E. [1] ; Lima, Carmen S. P. [1] ; Moriel, Patricia [2]
Total Authors: 15
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Fac Pharmaceut Sci, Campinas, SP - Brazil
[3] Univ Estadual Campinas, Clin Hosp, Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: CANCER MEDICINE; v. 8, n. 5, p. 2020-2030, MAY 2019.
Web of Science Citations: 0
Abstract

The protective antioxidant activity of acetylcysteine (NAC) against toxicity due to cisplatin has been reported in experimental models; however, its efficacy in patients has not been elucidated. The aim of this study was to investigate the possible protective effect of NAC on cisplatin-induced toxicity and the effect of NAC on clinical response and oxidative stress in patients treated for head and neck cancer. This was a randomized, double-blind, placebo-controlled trial conducted in patients receiving high-dose cisplatin chemotherapy concomitant to radiotherapy. Patients were randomly assigned to groups and received: (a) 600 mg NAC syrup, orally once daily at night for 7 consecutive days or (b) placebo, administered similarly to NAC. Nephro-, oto-, hepato-, myelo-, and gastrointestinal toxicities, clinical responses, and plasma and cellular markers of oxidative stress were evaluated. Fifty-seven patients were included (n = 28, NAC arm; and n = 29, placebo arm). A high prevalence of most types of toxicities was observed after cisplatin chemotherapy; however, the parameters were similar between the two groups. There was a predominance of partial response to treatment. In the cellular and plasmatic oxidative stress analyses, minor differences were observed. Overall, there was no statistically significant difference between the groups for all outcomes. These findings show that low-dose oral NAC does not protect patients with head and neck cancer from cisplatin-induced toxicities and oxidative stress. The antitumor efficacy of cisplatin was apparently not impaired by NAC. (AU)

FAPESP's process: 17/17728-8 - Mitochondrial function and dysfunction: implications for aging and associated diseases
Grantee:Aníbal Eugênio Vercesi
Support type: Research Projects - Thematic Grants
FAPESP's process: 14/04744-7 - Evaluation of the use of N-acetylcysteine attenuating cisplatin-induced toxicities by oxidative stress in head and neck cancer patients
Grantee:Marília Berlofa Visacri
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 14/18294-3 - Evaluation of the use of N-acetylcysteine attenuating cisplatin-induced toxicities by oxidative stress in head and neck cancer patients
Grantee:Patricia Moriel
Support type: Regular Research Grants
FAPESP's process: 15/01793-0 - Study of adverse reactions , quality of life and cellular oxidative stress in head and neck cancer patients in treatment with cisplatin and radiotherapy
Grantee:Júlia Coelho França Quintanilha
Support type: Scholarships in Brazil - Master